Aprea Therapeutics, Inc. Logo

Aprea Therapeutics, Inc.

Developing precision cancer therapies targeting DNA Damage Response for solid tumors.

APRE | US

Overview

Corporate Details

ISIN(s):
US03836J1025
LEI:
Country:
United States of America
Address:
3805 OLD EASTON ROAD, 18902 DOYLESTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics through precision oncology. The company specializes in synthetic lethality-based therapies that target DNA Damage Response (DDR) pathways. Aprea's pipeline features small molecule drug candidates designed to maximize clinical efficacy while minimizing toxicity. The company is actively conducting clinical trials to evaluate its programs in patients with advanced solid tumors, aiming to provide new treatment options and improve outcomes for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aprea Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aprea Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aprea Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
LAVA Therapeutics NV Logo
Develops bispecific gamma delta T cell engagers for solid and hematologic cancers.
United States of America LVTX
Lavipharm S.A. Logo
Develops & distributes Rx/OTC medicines, supplements & cosmetics for key therapeutic areas.
Greece LAVI
Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.
United States of America LBRX
Legend Biotech Corp Logo
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America LEGN
LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America LIMN

Talk to a Data Expert

Have a question? We'll get back to you promptly.